Open Access- https://doi.org/10.7774/cevr.2024.13.3.259
Urinary incontinence after COVID-19 vaccination: a case study in an 8-year-old boy.
Translate Article 
Take Notes There have been many studies on the adverse effects of coronavirus disease 2019 (COVID-19) vaccines but the urinary incontinence after COVID-19 vaccination is rare. Here, we report an 8-year-old boy presented to outpatient department, Thai Binh University of Medicine Hospital, Thai Binh, Vietnam with complaints of urinary incontinence for the past 2 weeks, following the first dose of the messenger RNA vaccine. He had no other abnormalities in clinical and laboratory exams. This clinical situation suggested vaccine side effects. No specific treatment was administered upon diagnosis without toilet and bladder training. Subsequent monitoring revealed a gradual reduction in symptoms over 2 months, with complete recovery achieved at the 14th week from the onset of symptoms, without necessitating any medical intervention. This case highlights the need for thorough evaluation and assessment of potential adverse effects following vaccination, including uncommon presentations.
- Research Article
1 - 10.1016/j.amj.2022.02.007
- Mar 17, 2022
- Air Medical Journal
Vaccination
- Research Article
- 10.1016/j.ptdy.2021.07.022
- Aug 1, 2021
- Pharmacy Today
Immunization Update 2021
- Research Article
- 41
- 10.1111/ajt.16516
- Feb 28, 2021
- American Journal of Transplantation
Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020.
- Research Article
- 45
- 10.1111/ajt.16517
- Feb 28, 2021
- American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021.
- Front Matter
- 4
- 10.1016/j.fertnstert.2021.05.083
- May 14, 2021
- Fertility and Sterility
Should women undergoing in vitro fertilization treatment or who are in the first trimester of pregnancy be vaccinated immediately against COVID-19
- Research Article
- 3
- 10.1016/j.jgo.2022.07.005
- Jul 15, 2022
- Journal of Geriatric Oncology
Updated International Society of Geriatric Oncology COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer
- Research Article
- 10.1097/jom.0000000000002770
- Dec 14, 2022
- Journal of Occupational & Environmental Medicine
Ethical Considerations Surrounding Employment Mandated Coronavirus Disease 2019 Vaccination and Allergy Skin Testing for the Coronavirus Disease 2019 Vaccine.
- Discussion
- 10.1016/j.jaip.2021.03.016
- Jun 1, 2021
- The Journal of Allergy and Clinical Immunology: In Practice
Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”
- Research Article
- 25
- 10.1016/j.molmed.2022.04.012
- May 3, 2022
- Trends in molecular medicine
COVID-19 vaccines in pregnancy.
- Supplementary Content
- 21
- 10.1007/s10238-022-00836-x
- May 24, 2022
- Clinical and Experimental Medicine
Hyperviscosity syndrome (HVS) recently emerged as a complication of coronavirus disease 2019 (COVID-19) and COVID-19 vaccines. Therefore, the objectives of this critical review are to establish the association between COVID-19 and COVID-19 vaccines with the development of HVS. HVS may develop in various viral infections due to impairment of humoral and cellular immunity with elevation of immunoglobulins. COVID-19 can increase blood viscosity (BV) through modulation of fibrinogen, albumin, lipoproteins, and red blood cell (RBC) indices. HVS can cause cardiovascular and neurological complications in COVID-19 like myocardial infarction (MI) and stroke. HVS with or without abnormal RBCs function in COVID-19 participates in the reduction of tissue oxygenation with the development of cardio-metabolic complications and long COVID-19. Besides, HVS may develop in vaccine recipients with previous COVID-19 due to higher underlying Ig concentrations and rarely without previous COVID-19. Similarly, patients with metabolic syndrome are at the highest risk for propagation of HVS after COVID-19 vaccination. In conclusion, COVID-19 and related vaccines are linked with the development of HVS, mainly in patients with previous COVID-19 and underlying metabolic derangements. The possible mechanism of HVS in COVID-19 and related vaccines is increasing levels of fibrinogen and immunoglobulins. However, dehydration, oxidative stress, and inflammatory reactions are regarded as additional contributing factors in the pathogenesis of HVS in COVID-19. However, this critical review cannot determine the final causal relationship between COVID-19 and related vaccines and the development of HVS. Prospective and retrospective studies are warranted in this field.
- Front Matter
- 34
- 10.1016/j.jaip.2021.01.022
- Jan 30, 2021
- The Journal of Allergy and Clinical Immunology. in Practice
The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World
- Research Article
- 5
- 10.1016/j.anai.2022.02.024
- Mar 4, 2022
- Annals of Allergy, Asthma & Immunology
Graded coronavirus disease 2019 vaccine administration: A safe alternative to vaccine avoidance
- Research Article
- 20
- 10.1016/j.kint.2022.07.018
- Aug 11, 2022
- Kidney International
The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases
- Front Matter
- 104
- 10.1053/j.ajkd.2021.06.004
- Jun 25, 2021
- American Journal of Kidney Diseases
De Novo and Relapsing Glomerular Diseases After COVID-19 Vaccination: What Do We Know So Far?
- Discussion
- 19
- 10.1016/j.jns.2021.120102
- Dec 20, 2021
- Journal of the Neurological Sciences
Acute transverse myelitis after BNT162b2 vaccination against COVID-19: Report of a fatal case and review of the literature
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
